Fertility and adjuvant treatment in young women with breast cancer

Ann H. Partridge, Kathryn J Ruddy

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Women of childbearing age with breast cancer are often concerned about whether they will become infertile after treatment, and for those who wish to bear children, whether a subsequent pregnancy will alter their risk of disease recurrence. The risk of chemotherapy-related amenorrhea (CRA), menopause, and infertility appear to be related to patient age and type of treatment received, though data regarding actual fertility following treatment are limited. There are options available for fertility preservation for young women who wish to have a biologic child after breast cancer and are at risk for infertility. Options include cryopreservation of embryos, oocytes, ovarian tissue prior to treatment, and ovarian suppression through chemotherapy. However, most of these are considered experimental, and there are limited data regarding the safety of such strategies. There has been concern that pregnancy after breast cancer may worsen prognosis in light of the endocrine manipulations used to treat breast cancer, particularly for women with hormone sensitive disease. Several studies addressing the potential risk of pregnancy after breast cancer have not revealed any negative effect on prognosis. However, these studies have significant limitations, and concerns about a negative impact for some remain. Ongoing and future prospective studies evaluating fertility and pregnancy issues for young breast cancer survivors are warranted for this vulnerable population facing this difficult issue.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalBreast
Volume16
Issue number2 SUPPL.
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Fertility
Breast Neoplasms
Pregnancy
Infertility
Therapeutics
Fertility Preservation
Drug Therapy
Cryopreservation
Amenorrhea
Vulnerable Populations
Menopause
Oocytes
Survivors
Embryonic Structures
Hormones
Prospective Studies
Safety
Recurrence

Keywords

  • Amenorrhea
  • Breast cancer
  • Fertility
  • Pregnancy
  • Young women

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Fertility and adjuvant treatment in young women with breast cancer. / Partridge, Ann H.; Ruddy, Kathryn J.

In: Breast, Vol. 16, No. 2 SUPPL., 2007, p. 175-181.

Research output: Contribution to journalArticle

Partridge, Ann H. ; Ruddy, Kathryn J. / Fertility and adjuvant treatment in young women with breast cancer. In: Breast. 2007 ; Vol. 16, No. 2 SUPPL. pp. 175-181.
@article{8cf149438eb94262b8216cf60747137a,
title = "Fertility and adjuvant treatment in young women with breast cancer",
abstract = "Women of childbearing age with breast cancer are often concerned about whether they will become infertile after treatment, and for those who wish to bear children, whether a subsequent pregnancy will alter their risk of disease recurrence. The risk of chemotherapy-related amenorrhea (CRA), menopause, and infertility appear to be related to patient age and type of treatment received, though data regarding actual fertility following treatment are limited. There are options available for fertility preservation for young women who wish to have a biologic child after breast cancer and are at risk for infertility. Options include cryopreservation of embryos, oocytes, ovarian tissue prior to treatment, and ovarian suppression through chemotherapy. However, most of these are considered experimental, and there are limited data regarding the safety of such strategies. There has been concern that pregnancy after breast cancer may worsen prognosis in light of the endocrine manipulations used to treat breast cancer, particularly for women with hormone sensitive disease. Several studies addressing the potential risk of pregnancy after breast cancer have not revealed any negative effect on prognosis. However, these studies have significant limitations, and concerns about a negative impact for some remain. Ongoing and future prospective studies evaluating fertility and pregnancy issues for young breast cancer survivors are warranted for this vulnerable population facing this difficult issue.",
keywords = "Amenorrhea, Breast cancer, Fertility, Pregnancy, Young women",
author = "Partridge, {Ann H.} and Ruddy, {Kathryn J}",
year = "2007",
doi = "10.1016/j.breast.2007.07.029",
language = "English (US)",
volume = "16",
pages = "175--181",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Fertility and adjuvant treatment in young women with breast cancer

AU - Partridge, Ann H.

AU - Ruddy, Kathryn J

PY - 2007

Y1 - 2007

N2 - Women of childbearing age with breast cancer are often concerned about whether they will become infertile after treatment, and for those who wish to bear children, whether a subsequent pregnancy will alter their risk of disease recurrence. The risk of chemotherapy-related amenorrhea (CRA), menopause, and infertility appear to be related to patient age and type of treatment received, though data regarding actual fertility following treatment are limited. There are options available for fertility preservation for young women who wish to have a biologic child after breast cancer and are at risk for infertility. Options include cryopreservation of embryos, oocytes, ovarian tissue prior to treatment, and ovarian suppression through chemotherapy. However, most of these are considered experimental, and there are limited data regarding the safety of such strategies. There has been concern that pregnancy after breast cancer may worsen prognosis in light of the endocrine manipulations used to treat breast cancer, particularly for women with hormone sensitive disease. Several studies addressing the potential risk of pregnancy after breast cancer have not revealed any negative effect on prognosis. However, these studies have significant limitations, and concerns about a negative impact for some remain. Ongoing and future prospective studies evaluating fertility and pregnancy issues for young breast cancer survivors are warranted for this vulnerable population facing this difficult issue.

AB - Women of childbearing age with breast cancer are often concerned about whether they will become infertile after treatment, and for those who wish to bear children, whether a subsequent pregnancy will alter their risk of disease recurrence. The risk of chemotherapy-related amenorrhea (CRA), menopause, and infertility appear to be related to patient age and type of treatment received, though data regarding actual fertility following treatment are limited. There are options available for fertility preservation for young women who wish to have a biologic child after breast cancer and are at risk for infertility. Options include cryopreservation of embryos, oocytes, ovarian tissue prior to treatment, and ovarian suppression through chemotherapy. However, most of these are considered experimental, and there are limited data regarding the safety of such strategies. There has been concern that pregnancy after breast cancer may worsen prognosis in light of the endocrine manipulations used to treat breast cancer, particularly for women with hormone sensitive disease. Several studies addressing the potential risk of pregnancy after breast cancer have not revealed any negative effect on prognosis. However, these studies have significant limitations, and concerns about a negative impact for some remain. Ongoing and future prospective studies evaluating fertility and pregnancy issues for young breast cancer survivors are warranted for this vulnerable population facing this difficult issue.

KW - Amenorrhea

KW - Breast cancer

KW - Fertility

KW - Pregnancy

KW - Young women

UR - http://www.scopus.com/inward/record.url?scp=35648946243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35648946243&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2007.07.029

DO - 10.1016/j.breast.2007.07.029

M3 - Article

C2 - 17804236

AN - SCOPUS:35648946243

VL - 16

SP - 175

EP - 181

JO - Breast

JF - Breast

SN - 0960-9776

IS - 2 SUPPL.

ER -